MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Tue Nov 19 00:00:00 GMT-05:00 2019
Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with HER2 Positive Metastatic Breast Cancer to be Presented at SABCS
Download
Wed Nov 06 00:00:00 GMT-05:00 2019
Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer Portfolio
Download
Mon Nov 04 00:00:00 GMT-05:00 2019
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Download
Thu Oct 31 00:00:00 GMT-05:00 2019
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
Download
Thu Oct 17 00:00:00 GMT-05:00 2019
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Download
Tue Sep 10 00:00:00 GMT-05:00 2019
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
Download
Tue Sep 10 00:00:00 GMT-05:00 2019
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Download
Mon Sep 09 00:00:00 GMT-05:00 2019
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
Download
Wed Aug 21 00:00:00 GMT-05:00 2019
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung Cancer
Download
Mon Aug 12 00:00:00 GMT-05:00 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Download